Login
$MANE
$128.05 +$0.00 (0.0%) After hours

$MANE 8-K SEC Filings

Filed On Filing
10 Nov 2026 8-K: Results of Operations and Financial Condition

Positive topline results from Phase 3 Study ‘304’ and positive 12-month data from Phase 2/3 Study ‘302’ position VDPHL01 to potentially become the first oral treatment to receive FDA approval for pattern hair loss in nearly 30 years

09 Nov 2026 8-K: Regulation FD Disclosure; Other Events

Study ‘302’ Part B Phase 3 Topline Data in Males with Mild-to-Moderate Pattern Hair Loss November 2026 NOVEMBER 2026

19 Oct 2026 8-K: Regulation FD Disclosure; Other Events

VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and secondary endpoints with high statistical significance in both active treatment arms evaluating once-daily (QD) and twice-daily (BID) admini...

11 Aug 2026 8-K: Results of Operations and Financial Condition

Positive topline results from open-label Phase 2 Study ‘207’ evaluating VDPHL01 in female pattern hair loss demonstrated rapid onset and consistent hair growth

15 Jul 2026 8-K: Regulation FD Disclosure; Other Events

Study ‘207’ Phase 2 Topline Open Label Data in Females with Mild-to-Moderate Pattern Hair Loss July 2026

12 May 2026 8-K: Results of Operations and Financial Condition

Positive topline results from Phase 2/3 Study ‘302’ position VDPHL01 to potentially become the first FDA-approved oral treatment for pattern hair loss in nearly 30 years

01 May 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

This Securities Purchase Agreement (this “Agreement”) is dated as of April 29, 2026, between Veradermics, Incorporated, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including ...

27 Apr 2026 8-K: Results of Operations and Financial Condition

Veradermics, Incorporated (the “Company”) reports that it had a preliminary unaudited amount of cash, cash equivalents and marketable securities of approximately $390.8 million as of March 31, 2026. This amount is preliminary and unaudit...

27 Apr 2026 8-K: Regulation FD Disclosure; Other Events

Study 302 Phase 2/3 Topline Data in Males with Mild-to-Moderate Pattern Hair Loss April 2026

30 Mar 2026 8-K: Results of Operations and Financial Condition

Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates

05 Feb 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year

An annual meeting of the stockholders of Veradermics, Incorporated, a Delaware corporation (the “Corporation”), for the election of directors to succeed those whose terms expire and for the transaction of such other business as may prope...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support